Latest Dorsavi (ASX:DVL) News

Appen led the technology market with a 45.73% weekly rise, while Synertec and InteliCare also gained more than 27%.
AI services, defence systems, critical infrastructure and recurring software revenue drove the week’s strongest company updates.

dorsaVi has confirmed its RRAM memory and neuromorphic IP operate synergistically, projecting up to 10x performance gains for robotics and exoskeletons. The company also finalized its first integrated RRAM-CMOS validation chip design, advancing towards tape-out and commercialisation.

dorsaVi has unveiled Sensor v6.5, its first wearable sensor that processes and acts on movement data in real time without cloud reliance, marking a key milestone in wearable Physical AI technology.

Small-cap tech trading split into two clear camps this week: profit-backed winners and capital-raising laggards. Big contracts, rising recurring revenue and a major takeover kept money flowing into selected names.

dorsaVi has moved from design to silicon manufacturing with the tape-out of its first 22-nm RRAM-CMOS validation chip, aiming to prove its advanced memory platform for AI and robotics applications.

Space batteries, telecom AI and a healthcare software leadership change drove the week’s biggest moves in small-cap tech. Capital raisings and debt deals also shaped trading, with several early jumps fading as investors weighed dilution and execution risk.

dorsaVi has completed the design of its first integrated RRAM-CMOS validation chip, featuring self-checking write-and-verify, compute-in-memory capabilities, and scalable integration on commercial CMOS wafers. The milestone sets the stage for fabrication and commercial engagement in high-value edge AI markets.

dorsaVi has raised $500,000 through the exercise of 25 million unlisted options by key shareholders, reinforcing confidence in its advanced AI and neuromorphic semiconductor projects. The capital will accelerate development of its 22nm node technology targeting medical and industrial robotics markets.

A brutal sell-off in a few small caps sat alongside takeover bids, fresh capital raisings and strong gains in medtech. The week split the market in two: buyers chased clear funding and approval news, while weaker stories sank fast after reopening.

Capital raisings drove the week in ASX tech, with investors backing AI and data centre spending but punishing deep discounts. The biggest moves came from small-cap fundraisings, while AI infrastructure names drew the clearest buying support.

dorsaVi has secured exclusive rights to two key robotics patents from NTU Singapore, filling critical gaps in safety control and data acquisition to expand into collaborative robotics and exoskeleton markets.

A handful of extreme moves set the tone, from DXN’s explosive AI data centre rerating to steep sell-offs in small-cap explorers. Deals, funding and fresh drilling results drove the week, but several gap-ups lost steam as traders banked profits.